Consumption of Butylated Starch Alleviates the Chronic Restraint Stress-Induced Neurobehavioral and Gut Barrier Deficits Through Reshaping the Gut Microbiota

Peijun Tian1,2†, Huiyue Zhu1,2†, Xin Qian1,2, Ying Chen1,2, Zheng Wang1,2, Jianxin Zhao1,2,3,4, Hao Zhang1,2,3,4,5, Gang Wang1,2,4* and Wei Chen1,2,3

1 State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China, 2 School of Food Science and Technology, Jiangnan University, Wuxi, China, 3 National Engineering Research Center for Functional Food, Jiangnan University, Wuxi, China, 4 (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, China, 5 Wuxi Translational Medicine Research Center, Jiangsu Translational Medicine Research Institute, Wuxi, China

The beneficial effect of short-chain fatty acids (SCFAs) on host health has been well recognized based on the booming knowledge from gut microbiome research. The role of SCFA in influencing psychological function is highlighted in recent years but has not been fully elucidated. In this study, the SCFA-acylated starches were used to accomplish a sizeable intestine-targeted release of the SCFAs, and the neurobehavioral, immunological, and microbial effects were further investigated. Acetylated-, butylated-, and isobutylated-starch could attenuate the depression-like behaviors and excessive corticosterone production in chronically stressed mice. Butylated-starch significantly reduced the colonic permeability via increasing the tight junction proteins (including ZO-1, Claudin, and Occludin) gene expression and reduced the level of the inflammatory cytokines (including IL-1β and IL-6). The butylated starch’s neurological and immunological benefits may be derived from the gut microbiome modifications, including normalizing the abundance of certain beneficial microbes (Odoribacter and Oscillibacter) and metabolomic pathways (Tryptophan synthesis and Inositol degradation). The present findings further validate the brain-beneficial effect of butyrate and offer novel guidance for developing novel food or dietary supplements for improving mental health.

Keywords: butyrate, starch, depression, gut barrier, inflammation

INTRODUCTION

Short-chain fatty acids (SCFAs) are the primary products of gut microbial fermentation from the undigested dietary fibers (1). Acetate, propionate, and butyrate (or isobutyrate) are the three major SCFAs (2). The regular communication between SCFAs and hosts participates in multiple physiological processes, including nutrients metabolism and immune system function (3). These SCFAs have been demonstrated to affect the host through multiple mechanisms: (a) SCFAs are
energy sources for gastrointestinal mucosal cells. In particular, butyrate is the primary energy source for colonocytes (4). (b) SCFAs are the ligands of G Protein-Coupled Receptors (GPCR). The activation of GPR43 and GPR41 via SCFAs promotes the secretion of various hormones involving blood glucose maintenance, such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine (PYY) (5, 6). (c) SCFAs could act as the histone deacetylases (HDACs) and therefore normalize the gene expression involving cell proliferation and anti-inflammatory process (6).

In recent years, growing evidence suggested that SCFAs are also a class of signaling molecules regulating brain function through the gut-brain axis (7). For example, feeding the obese mice with butyrate could activate the vagus nerve, which suppresses the appetite-related hormones’ release and then reduces the weight of mice (8). Besides, SCFAs secreted into the circulation could reach the brain and improve the blood-brain barrier’s permeability by up-regulating the tight junction protein expression (9). Direct intake of SCFAs also showed noticeable neuromodulation effects. A prior oral supplementation of the SCFA mixture (acetate, propionate, and butyrate) could prevent the mice from the neurobehavioral deficits induced by the repeated psychosocial stress, including depression and anxiety-like behaviors and impaired gut barrier function (10). In addition, our previous studies also proved that the SCFAs facilitate the biosynthesis of gut serotonin and the 5-hydroxytryptophan’s circulation, and this mechanism may account for the antidepressant-like effect of some psychobiotic strains such as the *Bifidobacterium longum* CCFM687 and *Bifidobacterium breve* CCFM1025 (11–13).

Previous research from our group indicated that intaking of SCFA-acylated starch, which results in increased SCFAs levels in the large intestine, alleviates the constipation symptoms in mice (14). All the evidence indicates the SCFAs possess great psychotropic potential. Inspired by the reported findings, here we use the SCFA-acylated starches as the dietary supplement to investigate the role of each SCFA in managing stress-induced neurobehavioral, immunological, and gut microbial abnormalities.

**MATERIAL AND METHODS**

**Animal Experiment**

The animal procedures were approved by the Ethics Committee of Experimental Animals at Jiangnan University [JN.No20190930c0 501205(256)], following Directive 2010/63/EU guidelines. Animals were allowed to adapt to the environment (21°C~23°C, 50%~60% of humidity, 12:12h light-dark cycle) for seven days before the experiment. The group and experimental schedule are shown in Figure 1A (N=8-10 per group).

---

**FIGURE 1** | The effect of the SCFA-acylated starches on the neurobehavioral phenotype. (A) The animal experiment schedule. (B) Open field test. (C) Tail suspension test. (D) Forced swim test. (E) Serum corticosterone levels. Except for the control, all groups are given two-week chronic restraint stress. Data are mean with SEM (n=6-10 per group for each test). ## P<0.01 in the unpaired t-tests. *P<0.05, **P<0.01, ***P<0.001 in the one-way ANOVA followed by Dunnett’s multiple comparisons test against the Depressed group.
Chronic Restraint Stress
The chronic restraint stress (CRS) paradigm was used to establish the depression-like phenotype (15). Mice were exposed to the restraint stress three h per day (from 09:00 to 15:00 every day, 1 hour/each time, three times in total) for 14 consecutive days. Each mouse was put into a 50 mL plastic tube with a breathing hole and no food and water access. Mice in the control group fasted simultaneously during the CRS procedure. After the stress, all the mice were placed back in their home cages.

Behavioral Tests
The protocols of open field test (OFT), tail suspension test (TST), and forced swim test (FST) were described in detail in our previously published papers (13). For the OFT, mice were assessed for their locomotor activity in a square arena (50 cm×50 cm) enclosed by continuous opaque walls made of plexiglass. Animals were monitored for 10 minutes, and the time spent in the center zone and active time during the whole period were measured. For the TST, animals were hanged using adhesive tape to fix the tails to a suspension bar (30 cm high from the floor). Locomotor activity is monitored for six minutes, and the duration of immobility was measured. For the FST, mice were allowed to swim in the water with a temperature of 23–25°C, and the immobility time was recorded during the ten-minute swimming. All mice are trained to swim for 15 minutes the day before the test. Before all the behavioral tests, animals were habituated to the room for one hour. All tests were performed under dim light (60 lux) and monitored by the video tracking system (Ethovision version 13, Noldus, Netherlands).

SCFA-Acylated Starches Preparation
SCFA-acylated starches were prepared as previously described (16, 17). Briefly, 40% (w/v) high amylopectin corn starch solution was continuously stirred in the water bath with a constant temperature of 40°C. The pH was maintained at 8.00 by the addition of dilute NaOH (0.5 mol/L). Meanwhile, the acetic anhydride, propionic anhydride, butyric anhydride, and isobutyric anhydride were dripped into the starch solution, respectively, to reach a final amount of 20% (w/v). The solution was continued to be stirred for 2 hours, then adjusted to a pH of 5.70 using HCl (0.5 mol/L). The precipitation was collected by centrifuge (6000×g, 5 min) and washed with water until the liquor was neutral. After a suction filtration at vacuum (-20 kPa, 10 min), the precipitation was freeze-dried to get the SCFA-acylated starches. The starch solution without adding anhydride but processed as the same procedure above was used as control. The methods of measuring the degree of substitution of the SCFA-acylated starches and the results were described in Supplemental 1.1.

SCFAs Determination
SCFAs levels were measured as previously described with some modifications (12, 18). Fecal samples from the distal ileum and cecum are weighed (about 50 mg), homogenized, and lyophilized. The samples were soaked in 500 μl of saturated NaCl solution for 30 min. The mixture was homogenized, and 40 μL 10% (w/v) sulfuric acid was added. 1 mL ether was added to the mixture and vortexed following centrifugation (18,000 g, 15 min, 4°C). 500 μL supernatant was filtered (0.22 μm) before further analysis. SCFA concentrations were determined in the TSQ 9000 GC-MS system (Thermo Scientific) equipped with an Rtx-WAX capillary column, using helium as carrier gas (flow rate of 0.89 mL/min). A gradient profile of the oven temperature was used, starting at 100°C and increased to 140°C (7.5°C/min), then increased to 200°C (6.0°C/min) and maintained for 3 min. The ion source and interface temperature in the mass spectrometer were 220°C and 250°C, respectively.

Hormones and Cytokines Determination
Serum corticosterone and inflammatory cytokines (TNF-α, IL-β, and IL-6) were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s protocol (SenBeijia Biological Technology Co., Ltd., Nanjing, China).

Gene Transcription of the Tight Junction Proteins
Total RNA of the colon tissues was extracted using Trizol reagent (Invitrogen, USA). Complementary DNA was prepared using the HiFiScript gDNA Removal cDNA Synthesis Kit (ComWin Biotech Co., Ltd., China). Transcription levels of the zonula occludens-1 (ZO-1), Claudin, and Occludin were determined by quantitative PCR. The gene expression was normalized to Gapdh based on the cycle threshold (Ct) values and the 2^(-ΔΔCt) method. All samples are measured in triplicate. Primer sets information are shown in Supplemental Table S1.

16S rRNA-Amplicon Sequencing of the Fecal Microbiome
16S rRNA gene amplicon sequencing of the fecal microbiome was performed using universal primers (341F/806R, for V3-V4 region) as previously described. Raw data were processed using the QIIME2 software package, and the specialized bioinformatic analysis was performed using the online software of MicrobiomeAnalyst (https://www.microbiomeanalyst.ca), including alpha diversity, beta diversity, and network analysis (19, 20). Gut metabolic modules (GMMs) analysis was performed using the R version of the Gomixer tool as previously described (21, 22). Detailed bioinformatical methods are described in Supplemental 1.2.

Statistical Analysis
Data are presented as means with SEM. All data were checked for normality by the Shapiro-Wilk test. Unpaired Student’s t-test was performed between the Control and Depressed groups. One-way ANOVA followed by Dunnett’s multiple comparisons test against the Depressed group was performed to compare the effects of SCFA-acylated starches in the CRS-treated animals. A criterion for significance was set to P<0.05 in all comparisons. The P-value of multiple comparisons was adjusted by family-wise significance and confidence levels of 0.05 (95% confidence interval).
RESULTS

Consumption of SCFA-Acylated Starches Changed the Depressive Symptoms of Stressed Mice

A two-week CRS induced significantly depressive behaviors, such as the significantly reduced active time in the OFT (P=0.002; Figure 1B) and increased immobility time in the FST (P=0.011; Figure 1D). The immobility time in the TST was increased but without any statistical difference (P=0.308; Figure 1C). Acetylated, butylated, and isobutylated starch reversed the animal’s behavioral abnormality in the OFT (Figure 1B; P<0.001, P=0.044, P<0.001, respectively) and TST (P=0.011, P=0.007, P=0.013, respectively; Figure 1C). Butylated starch also reduced the animal’s immobility time in the FST, with a trend statistical difference (P=0.056, Figure 1D).

SCFA-Acylated Starches Increased the SCFA Levels in the Large Intestine

In the distal ileum, the propionate (P=0.001), butyrate (P=0.009), and isobutyrate (P<0.001) levels were significantly increased when compared with the depressed mice, while the acetate level was not changed by the acetylated starch (Figures 2A–D). In the cecum, the acetate (P=0.044) and butyrate (P=0.024) levels were significantly decreased in the depressed mice, and the abnormalities were reversed by the acetylated (P=0.035) and butylated (P=0.001) starch treatment (Figures 2E, G). The cecum propionate (P=0.009) and isobutyrate (P=0.001) levels were also significantly increased when compared to the depressed mice (Figures 2F, H). All above data indicated that the SCFA-acylated starches resulted in a release of SCFAs in the gut, especially in the large intestine.

Butylated Starch Improved the Gut Barrier Function of Depressed Mice

Gut barrier function was evaluated by the gene expression of tight junction protein levels. CRS induced a significant reduction of the transcriptional level of the ZO-1 gene (P=0.049), the Claudin gene (P=0.038), and the Occludin gene (P=0.048). Intriguingly, the butylated starch showed a superior effect to others to restore the gut barrier (Figures 3A–C). The deficit of gut barrier resulted in increased serum lipopolysaccharide (LPS; Figure 3D) and inflammatory cytokines, including serum IL-1β (P=0.001), IL-6 (P<0.001), and TNF-α (P=0.074) (Figures 3E–G). Butylated starch significantly reduced the serum IL-1β (P=0.025) and IL-6 (P=0.002) levels. The isobutyrate starch could also reduce the serum IL-6 level (P=0.036; Figure 3F). In addition, butylated starch reduced the serum TNF-α level, with a trend statistical difference (P=0.054, Figure 3D).

FIGURE 2 | The SCFAs levels in the ileum and cecum. (A–D) Acetate, propionite, butyrate, and isobutyrate levels in the ileum. (E–H) Acetate, propionite, butyrate, and isobutyrate levels in the cecum. Except for the control, all groups are given two-week chronic restraint stress. Data are mean with SEM (n=6-10 per group for each test). #P<0.05 in the unpaired t-tests. *P<0.05, **P<0.01, ***P<0.001 in the unpaired t-tests.
Butylated Starch Changed the Gut Microbial Composition and Function of Depressed Mice

CRS induced a significantly increased gut microbial alpha-diversity, as reflected by the Shannon (P<0.001) and Chao1 (P=0.001) index (Figures 4A, B). The butylated starch treatment normalized the Chao1 changes (P=0.003; Figure 4B). Besides, the beta diversity estimated using Aitchison distance and principal component analysis (PCA) showed that every two groups are significantly different (PERMANOVA results in Figure 4C). The linear discriminant analysis (LDA) effect size algorithm (LEfSe) identified five genus-level biomarkers of the butylated starch treated gut microbiome, including Bacteroides, Ruminiclostridium, Odoribacter, and Oscillibacter (Figure 4D). The relative abundance of these four taxa was all significance decreased under stress, and the butylated starch treatment increased the Odoribacter (P=0.072) and Oscillibacter (P=0.048) abundances (Figure 4E).

DISCUSSION

In the present study, oral intake of SCFA-acylated starches could significantly increase the SCFAs levels in the large intestine, which improves the neurobiological conditions of the mice enduring chronic stress. In particular, the butylated starch could significantly enhance the gut barrier integrity and reduce inflammation. The butylated starch also improved the gut microbial composition and function, contributing to the recovery from the stress-induced disorder.

Although accumulated research have proved the beneficial role of SCFAs in regulating brain function, using dietary SCFAs to address psychological disorders did not make good progress (7). Since most SCFAs have a strong smell, the direct intake of SCFAs could cause olfactory discomfort and may affect neurobehavioral performance (23). Moreover, oral intake SCFAs are primarily absorbed by the upper intestine, which cannot mimic the natural production of SCFAs in the large intestine (24, 25). Since current evidence that supports the SCFAs’ health effect is mainly generated from the research focused on the large intestine, direct oral intake of the SCFAs may not be the optimal choice (26). Intaking dietary fibers is another widely used way to enhance the SCFAs’ production (27, 28). However, the production of each SCFA cannot be quantitatively controlled, and the role of each SCFA is hard to identify.

Accumulating studies demonstrated that acylated starch has small enzyme resistance and could reach the large intestines (29, 30). Here, a catalytic reaction of corn starch with SCFA anhydrides was used to obtain the SCFA-acylated starches (31). These starches cannot be digested and absorbed when the degree of substitution was modified to the range of 0.2 to 0.3 (32). When reaching the large intestine, they are fermented by the gut microbiota and produce SCFAs, which are then absorbed and transported to the brain, providing health benefits.
microbiome and release the free SCFAs (16, 32). Our results reproduced the phenomenon, reflected as the higher SCFA levels in the cecum than in the ileum (Figure 2). Also, each starch only significantly increased the corresponding acid without affecting other acids’ levels (Figure 2). Although not very precise, to some extent, the administration of SCFA-acylated starches realize a sizeable intestine-targeted release and elevation of each SCFA, which offers a great model for us to further investigate the SCFA’s psychotropic effects.

A neurobehavioral change of stressed mice was observed in the acetylated-, butylated-, and isobutylated- starch treated mice, but only butylated starch significantly improved the gut barrier function and immune status. To investigate the underlying mechanisms, the gut microbiome was analyzed, and some interesting findings were observed. Butylated-starch treatment established a novel microbial structure that differs from healthy and depressed mice (Figure 4C). Specifically, the reduced Odoribacter and Oscillibacter abundance was largely recovered (Figure S2). Odoribacter is a common SCFA-producing microbe, and the deficit of Odoribacter has been correlated to many metabolic and immunological disorders, including chronic kidney disease (33), Crohn’s disease (34), and inflammatory bowel disease (35). A recent study proved that Odoribacter splanchnicus has very low adherent and inflammatory capacity to the enteroctyes or mucus and can secrete the outer membrane vesicles that exert anti-inflammatory action in the gut epithelium (36).

Oscillibacter is another microbial taxa that sensitively responded to stress (37, 38), and the abundance is found to be significantly decreased in significant depression disorder patients (39). In addition, the butylated-starch modified microbial function also facilitates the neurotransmission function through upregulating the Tryptophan synthesis and downregulating the Inositol degradation pathways. Tryptophan is the precursor of serotonin, which is a crucial neurotransmitter that regulating multiple brain functions. Inositol was widely verified to be efficacious in treating depression and obsessive-compulsive disorder, and the mechanism correlates to the enchantment of serotonin production via the 5-HT2 receptors (40, 41). Collectively, normalizing the key microbes and metabolomic pathways seems beneficial to the host’s immune and brain function.

CONCLUSIONS

In conclusion, the butylated starch could alleviate the chronic restraint stress-induced neurobehavioral and gut barrier deficits. The mechanisms may link to the modification of gut microbial composition and function. Butylated starch’s anti-depressant and anti-inflammatory effects further validate the beneficial role of SCFAs in host health and offer novel guidance for developing novel food or dietary supplements for improving mental health.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE182262.

ETHICS STATEMENT
The animal study was reviewed and approved by Ethics Committee of Experimental Animals at Jiangnan University (JN.No20190930c0501205[256]).

AUTHOR CONTRIBUTIONS
PT: conceptualization, investigation, writing-original draft, and funding acquisition. HuZ: investigation and formal analysis. YC, PT: conceptualization, investigation, writing-original draft, and funding acquisition. HaZ and JZ: supervision and funding acquisition. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Morrison DJ, Preston T. Formation of Short Chain Fatty Acids by the Gut Microbiota and Their Impact on Human Metabolism. *Gut Microbes* (2016) 7(3):189–200. doi: 10.1080/19490976.2015.1134082
2. Macfarlane S, Macfarlane GT. Regulation of Short-Chain Fatty Acid Production. *Proc Nutr Soc* (2003) 62(1):67–72. doi: 10.1079/PNS2002007
3. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell* (2016) 165(6):1332–45. doi: 10.1016/j.cell.2016.05.041
4. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The Microbiology of Butyrate Formation in the Human Colon. *FEBS Microbiol Lett* (2002) 217(2):133–9. doi: 10.1016/S0378-1097(02)01106-0
5. Tian P, Li B, He C, Song W, Hou A, Tian S, et al. Antidiabetic (Type 2) Effects of Lactobacillus G15 and Q14 in Rats Through Regulation of Intestinal Permeability and Microbiota. *Food Funct* (2016) 7(9):3789–97. doi: 10.1039/C6FO00831C
6. Li K-K, Tian P-J, Wang S-D, Lei P, Qu L, Huang J-P, et al. Targeting Gut Microbiota: Lactobacillus Alleviated Type 2 Diabetes via Inhibiting LPS Secretion and Activating GPR43 Pathway. *J Funct Foods* (2017) 38:561–70. doi: 10.1016/j.jff.2017.09.049
7. Dallie B, Van Oudenhove L, Vervliet B, Verbeke K. The Role of Short-Chain Fatty Acids in Microbiota–Gut–Brain Communication. *Nat Rev Gastroenterol Hepatol* (2019) 16(8):461–78. doi: 10.1038/s41575-019-0157-3
8. Chambers ES, Morrison DJ, Frost G. Control of Appetite and Energy Intake by SCFA: What are the Potential Underlying Mechanisms? *Proc Nutr Soc* (2015) 74(3):328–36. doi: 10.1017/S0033806014001657
9. Braniste V, Alasmak M, Kowal C, Anuar F, Abbaspour A, Tóth M, et al. The Gut Microbiota Influences Blood-Brain Barrier Permeability in Mice. *Sci Transl Med* (2014) 6(263):263ra158. doi: 10.1126/scitranslmed.3009759
10. van de Wouw M, Boehme M, Lyte JM, Wiley N, Strain C, O’Sullivan O, et al. Short-Chain Fatty Acids: Microbial Metabolites That Alleviate Stress-Induced Brain–Gut Axis Alterations. *J Physiol* (2018) 596(20):4923–44. doi: 10.1113/JP276431
11. Tian P, Bastiaanssen TF, Song L, Jiang B, Zhang X, Zhao J, et al. Unravelling the Microbial Mechanisms Underlying the Psychobiological Potential of a Bifidobacterium Breve Strain. *Mol Nutr Food Res* (2021) 2000704. doi: 10.1002/mnfr.202000704
12. Tian P, Wang G, Zhao J, Zhang H, Chen W. Bifidobacterium With the Role of 5-Hydroxytryptophan Synthesis Regulation Alleviates the Symptom of Depression and Related Microbiota Dysbiosis. *J Nutr Biochem* (2019) 66:43–51. doi: 10.1016/j.jnutbio.2019.01.007
13. Tian P, O’Riordan KJ, Lee Y-K, Wang G, Zhao J, Zhang H, et al. Towards a Psychobiotic Therapy for Depression: Bifidobacterium breve CCFM1025 Reverses Chronic Stress-Induced Depressive Symptoms and Gut Microbial Abnormalities in Mice. *Neurobiol Stress* (2020) 100216. doi: 10.1016/j.nysr.2020.100216
14. Li K, Tian P-J, Wang S-D, Lei P, Qu L, Huang J-P, et al. Targeting Gut Microbiota: Lactobacillus Alleviated Type 2 Diabetes via Inhibiting LPS Secretion and Activating GPR43 Pathway. *J Funct Foods* (2017) 38:561–70. doi: 10.1016/j.jff.2017.09.049
15. Zhu Y, Klomparsen EA, Guo S, Geng X. Neuroinflammation Caused by Mental Stress: The Effect of Chronic Restraint Stress and Acute Repeated Social Defeat Stress in Mice. *Neuro Res* (2019) 41(8):762–9. doi: 10.1080/01616412.2019.1615670
16. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can Protect From Enteropathogenic Infection Through Production of Acetate. *Nature* (2011) 469(7331):543–7. doi: 10.1038/nature09646
17. Han F, Liu M, Gong H, Lü S, Ni B, Zhang B. Synthesis, Characterization and Functional Properties of Low Substituted Acetylated Corn Starch. *Int J Biol Macromol* (2012) 50(4):1026–34. doi: 10.1016/j.ijbiomac.2012.02.030
18. Tian P, Zou R, Song L, Zhang X, Jiang B, Wang G, et al. Ingestion of Bifidobacterium Longum Subspecies Infantis Strain CCFM687 Regulated Emotional Behavior and the Central BDNF Pathway in Chronic Stress-Induced Depressive Mice Through Reshaping the Gut Microbiota. *Food Funct* (2019) 10(11):7588–98. doi: 10.1039/C9FO01630A
19. Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for Comprehensive Statistical, Functional, and Meta-Analysis of Microbiome Data. *Nat Protoc* (2020) 15(3):799–821. doi: 10.1038/s41596-019-0264-1
20. Dharwai A, Chong J, Habib S, King IL, Agellon LB, Xia J. MicrobiomeAnalyst: A Web-Based Tool for Comprehensive Statistical, Visual and Meta-Analysis of Microbiome Data. *Nucleic Acids Res* (2017) 45(21):W180–8. doi: 10.1093/nar/gkx295
21. Bastiaanssen T, Gururajan A, Wouw M, Moloney GM, Cryan JF. Volatility as a Concept to Understand the Impact of Stress on the Microbiome. *Psychoneuroendocrinology* (2021) 124:105047. doi: 10.1016/j.psyneuen.2020.105047
22. Valles-Colomer M, Falony G, Darzi Y, Tiggesdahl EF, Wang J, Tito RY, et al. The Neuroactive Potential of the Human Gut Microbiota in Quality of Life and Depression. *Nat Microbiol* (2019) 4(4):e23–32. doi: 10.1038/s41564-018-0337-x

FUNDING
This work was financially supported by the National Natural Science Foundation of China (No. 31972052, 32021005, 31820103010), the Fundamental Research Funds for the Central Universities (JUSRP22006, JUSRP51501), the China National Postdoctoral Program for Innovative Talents (BX2021114), China Postdoctoral Science Foundation (2021M691290), the Postdoctoral Science Foundation of Jiangsu Province (2021K127B), the Program of Collaborative Innovation Centre of Food Safety and Quality Control in Jiangsu Province.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.755481/full#supplementary-material
23. Breer H, Fleischer J, Strotmann J. The Sense of Smell: Multiple Olfactory Subsystems. *Cell Mol Life Sci* (2006) 63(13):1465–75. doi: 10.1007/s00018-006-0108-8.

24. Ferreira TM, Leonel AI, Melo MA, Santos RR, Cara DC, Cardoso VN, et al. Oral Supplementation of Butyrate Reduces Mucositis and Intestinal Permeability Associated With 5-Fluorouracil Administration. *Lipids* (2012) 47(7):669–78. doi: 10.1007/s11745-012-3680-3.

25. Ruppin H, Bar-Meir S, Soergel KH, Wood CM, Schmitt MG Jr. Absorption of Short-Chain Fatty Acids by the Colon. *Gastroenterology* (1980) 78(6):1500–7. doi: 10.1016/S0016-5085(19)30508-6.

26. Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, Neuroepigenetics and the Gut Microbiome: Can a High Fiber Diet Improve Brain Health? *Neurosci Lett* (2016) 625:56–63. doi: 10.1016/j.neulet.2016.02.009.

27. Mandaliya D, Patel S, Seshadri S. Fiber in Our Diet and its Role in Health and Disease. *Funct Food Hum Health Springer* (2018) 24:27–55. doi: 10.1007/978-981-13-1123-9_12.

28. Tan J, McKenzie C, Vuillermoz PJ, Gouverse G, Vinuesa CG, Mebius RE, et al. Novel Odoribacter Splanchnicus Strain and Its Outer Membrane Vesicles Exert Immunoregulatory Effects *In Vitro*. *Front Microbiol* (2020) 11:575455. doi: 10.3389/fmicb.2020.575455.

29. Balamurugan R, Pugazhendhi S, Balachander GM, Dharmalingam T, Mortimer EK, Gopalsamy GL, et al. Effect of Native and Acetylated Dietary Resistant Starches on Intestinal Fermentative Capacity of Normal and Stunted Children in Southern India. *Int J Environ Res Public Health* (2019) 16(20):3922. doi: 10.3390/ijerph16203922.

30. Englyst HN, Kingman SM, Cummings J. Classification and Measurement of Nutritionally Important Starch Fractions. *Eur J Clin Nutr* (1992) 46:S33–50.

31. Zhu J, Zhang S, Zhang B, Qiao D, Liu S, et al. Structural Features and Thermal Property of Propionylated Starches With Different Amylose/Amylopectin Ratio. *Int J Biol Macromol* (2017) 97:123–30. doi: 10.1016/j.jbiomac.2017.01.033.

32. Annison G, Illman RJ, Topping DL. Acetylated, Propionylated or Butyrylated Starches Raise Large Bowel Short-Chain Fatty Acids Preferentially When Fed to Rats. *J Nutr* (2003) 133(11):3523–8. doi: 10.1093/jn/133.11.3523.

33. Kim JE, Kim H-E, Park JI, Cho H, Kwak M-J, Kim B-Y, et al. The Association Between Gut Microbiota and Uremia of Chronic Kidney Disease. *Microorganisms* (2020) 8(6):907. doi: 10.3390/microorganisms8060907.

34. Van Limbergen J, Dunn K, Wine E, Sigall Boneh R, Bielawski J, Levine A. OP22 Crohn’s Disease Exclusion Diet Reduces Bacterial Dysbiosis Towards Healthy Controls in Paediatric Crohn’s Disease. *J Crohn’s Colitis* (2020) 14(Supplement_1):S019–20. doi: 10.1093/ecto-jcc/jja203.021.

35. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the Intestinal Microbiome in Inflammatory Bowel Disease and Treatment. *Genome Biol* (2012) 13(9):1–18. doi: 10.1186/gb-2012-13-9-r79.

36. Hiippala K, Barreto G, Burrello C, Diaz-Basabe A, Sutariina M, Kainulainen V, et al. Novel Odoribacter Splanchnicus Strain and Its Outer Membrane Vesicles Exert Immunoregulatory Effects *In Vitro*. *Front Microbiol* (2020) 11:575455. doi: 10.3389/fmicb.2020.575455.

37. Yang H-L, Li M-M, Zhou M-F, Huan F, Liu N, et al. Links Between Gut Dysbiosis and Neurotransmitter Disturbance in Chronic Restraint Stress-Induced Depressive Behaviours: The Role of Inflammation. *Research Square* (2021). doi: 10.21203/rs.3.rs-469197/v1.

38. Ma X, Zhang Y, Yu T, Qian M, Yang Z, Zhan X, et al. Early-Life Intervention Using Exogenous Fecal Microbiota Alleviates Gut Injury and Reduce Inflammation Caused by Weaning Stress in Piglets. *Front Microbiol* (2021) 12(671683). doi: 10.3389/fmicb.2021.671683.

39. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered Fecal Microbiota Composition in Patients With Major Depressive Disorder. *Brain Behav Immun* (2015) 48:186–94. doi: 10.1016/j.bbi.2015.03.016.

40. Fux M, Benjamin J, Belmaker R. Inositol Versus Placebo Augmentation of Serotonin Reuptake Inhibitors in the Treatment of Obsessive–Compulsive Disorder: A Double-Blind Cross-Over Study. *Int J Neuropsychopharmacol* (1999) 2(3):193–5. doi: 10.1017/S1461145799001546.

41. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of Inositol and Serotonin Reuptake Inhibitors in the Treatment of Depression. *Biol Psychiatry* (1999) 45(3):270–3. doi: 10.1016/S0006-3223(98)00145-0.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guarantied or endorsed by the publisher.

Copyright © 2021 Tian, Zhu, Qian, Chen, Wang, Zhao, Zhang, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.